Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease - a prospective observational study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10173666" target="_blank" >RIV/00216208:11110/13:10173666 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/13:10173666 RIV/00023884:_____/12:00007613

Výsledek na webu

<a href="http://dx.doi.org/10.1186/1471-2369-14-142" target="_blank" >http://dx.doi.org/10.1186/1471-2369-14-142</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1186/1471-2369-14-142" target="_blank" >10.1186/1471-2369-14-142</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease - a prospective observational study

Popis výsledku v původním jazyce

Background: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the developmentof LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markersto echocardiographic parameters in CKD population. Methods: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2-4. Mean follow-up was 36 +/- 10 months. Laboratory and echocardiographic data were collected 2-3 times, at the shortest interval of 12 months apart. Multiv

Název v anglickém jazyce

Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease - a prospective observational study

Popis výsledku anglicky

Background: Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the developmentof LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markersto echocardiographic parameters in CKD population. Methods: We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2-4. Mean follow-up was 36 +/- 10 months. Laboratory and echocardiographic data were collected 2-3 times, at the shortest interval of 12 months apart. Multiv

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2013

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

BMC Nephrology

ISSN

1471-2369

e-ISSN

—

Svazek periodika

14

Číslo periodika v rámci svazku

JUL

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

9

Strana od-do

—

Kód UT WoS článku

000322922500001

EID výsledku v databázi Scopus

—